Allergan Aesthetics received FDA approval for Skinvive by Juvéderm for the improvement of neck appearance, marking the second cleared indication for the product line. Skinvive, a smooth, cohesive HA formulation designed for superficial dermal placement, was previously approved for chin augmentation. The neck approval broadens the injectable's clinical utility in a high-visibility zone where practitioners increasingly seek alternatives to traditional volumizers and neuromodulators.
Injectables
FDA Approves Skinvive by Juvéderm for Neck Lines — New Indication Expands Allergan's Dermal Filler Portfolio
Allergan Aesthetics wins clearance for Skinvive in neck appearance improvement, adding a second indication to its HA-based injectable platform.
Skinvive now carries two FDA-cleared indications, expanding Allergan's injectable footprint in aesthetic anatomy.
For practice economics, this expansion matters: it creates a new revenue stream in an anatomical area where patient demand is rising but clinical options remain limited. Skinvive's mechanism—a smooth HA gel optimized for superficial placement—positions it differently from traditional cross-linked fillers like Juvéderm Ultra or Volbella, which are designed for deeper dermal or subdermal injection. Practices already carrying Allergan's portfolio can add this indication without new inventory complexity, though training on proper neck-specific injection technique will be essential to avoid common pitfalls like Tyndall effect or product migration.
Source: original report ↗
Frequently asked questions
What is Skinvive by Juvéderm and what is it used for?
Skinvive is a smooth, cohesive hyaluronic acid (HA) formulation designed for superficial dermal placement. It now has two FDA-approved indications: chin augmentation and improvement of neck appearance, making it distinct from traditional cross-linked fillers designed for deeper injection.
How is Skinvive different from other Juvéderm fillers like Ultra or Volbella?
Skinvive is optimized for superficial dermal placement, whereas Juvéderm Ultra and Volbella are designed for deeper dermal or subdermal injection. This difference in placement depth makes Skinvive better suited for fine lines and surface-level contouring in areas like the neck and chin.
What are the main risks of injecting Skinvive in the neck area?
The primary risks include Tyndall effect (a bluish discoloration from superficial placement) and product migration. Proper injection technique specific to neck anatomy is essential to minimize these complications, making practitioner training critical for this new indication.
Do I need to order new inventory to offer Skinvive for neck treatment?
No. If your practice already carries Allergan's portfolio, you can add the neck indication without new inventory complexity. However, you will need to ensure staff receive training on proper neck-specific injection technique to safely and effectively deliver this treatment.
Why is the neck indication significant for medical aesthetics practices?
The neck is a high-visibility zone with rising patient demand but limited clinical options beyond traditional volumizers and neuromodulators. This new indication creates a new revenue stream and gives practices a differentiated treatment option in an underserved anatomical area.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Seasoned Expat Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.